Bionano genomics news.

We believe this technology-centric view is holding us back from the answers to critical questions around the origin, diagnosis, severity and treatment of cancer and genetic disease. We believe the way to move forward is an inclusive one that reveals what other tools miss and unifies data across technologies into one view to maximize the ... NEW YORK – Bionano Genomics this week executed a new round of layoffs, GenomeWeb has learned. According to information obtained by GenomeWeb from former employees who wished to remain anonymous, the workforce reduction appears to impact around 60 employees, although company executives declined to comment.. …Nov 1, 2023 · Company Contact: Erik Holmlin, CEO Bionano Genomics, Inc. +1 (858) 888-7610 [email protected] Investor Relations: David Holmes Gilmartin Group +1 (858) 888-7625 [email protected] Bionano Announces Presentation of OGM Utility Across Key Applications at the American Society of Human Genetics (ASHG) Annual Meeting. Oct '23. Bionano Prices $80.0 Million Financing in Convertible Notes and Warrants, Announces Preliminary Q3 2023 Results, and Implements Streamlined Operational Plan. Oct '23.We believe this technology-centric view is holding us back from the answers to critical questions around the origin, diagnosis, severity and treatment of cancer and genetic disease. We believe the way to move forward is an inclusive one that reveals what other tools miss and unifies data across technologies into one view to maximize the ...

Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing ...Bionano Announces Presentation of OGM Utility Across Key Applications at the American Society of Human Genetics (ASHG) Annual Meeting. Oct '23. Bionano Prices $80.0 Million Financing in Convertible Notes and Warrants, Announces Preliminary Q3 2023 Results, and Implements Streamlined Operational Plan. Oct '23.

Discover how Bionano is striving to elevate health and wellness for all through optical genome mapping (OGM) solutions that transform the way the world sees the genome. Enter a new era of optical genome …Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine.

SAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication in Nature Communications demonstrating the utility of optical genome mapping (OGM) as an alternative to karyotyping (KT) and chromosomal microarray (CMA) for the evaluation of CRISPR-Cas9 edited human induced pluripotent stem cell (iPSC) lines in order to uncover possible pathogenic ...Submissions focused on a variety of applications including genetic disease, cancer, reproductive health, cell and gene therapy, and plant and animal research. SAN DIEGO, June 12, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the 2023 winners of its Innovator Research Grant program, including grand prize winner Dr ...SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the pricing of (i) $45.0 million aggregate principal amount of senior secured convertible notes ...SAN DIEGO, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation at the Cancer Genomics Consortium (CGC) 2023 Annual Meeting with a broad range of content covering the utility of optical genome mapping (OGM) for solid tumor and hematological malignancy cancer research, including scientific …

SAN DIEGO, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a study detailing the challenges associated with the detection and interpretation of causal variants in Mendelian disease, using a cohort of 4,577 families.The study authors conducted a comprehensive analysis of samples from …

Bionano's second strategic pillar is to "delight our customers with robust products that are suitable for routine use at scale," he said. In addition to building a strong field support team, Bionano has a number of planned product updates, which include updates to the company's DNA isolation and labeling chemistries as well as integrating OGM ...

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that optical genome mapping (OGM) was included for the first time in Thompson and Thompson... Bionano to Report Third Quarter 2023 Financial Results and Host a Conference Call and Webcast on November 8, 2023 Globe Newswire • 26 days ago.Apr 17, 2023 · Apr. 17, 2023 11:19 AM ET Bionano Genomics, Inc. (BNGO) By: Jonathan Block, SA News Editor 9 Comments. Lemon_tm. Bionano Genomics ( NASDAQ: BNGO) is off 19% in Monday morning trading after selling ... SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the pricing of (i) $45.0 million aggregate principal amount of senior secured convertible notes ...Over the past 30 days, the shares of Bionano Genomics Inc (NASDAQ:BNGO) have changed 24.81%. Short interest in the company has seen 7.08 million shares shorted with days to cover at 6.06. Wall Street analysts have a consensus price target for the stock at $12.33, which means that the shares’ value could jump 86.54% from current levels.UPDATE - Bionano Announces Preliminary Q1 2023 Results and Business Updates. Preliminary Q1 total revenue expected to be between $7.3 and $7.5 million, which would represent an estimated increase of 28% to 32% over Q1 2022. Installed base of Saphyr® systems reached 259 as of March 31, 2023, which represents growth of the …Following the downgrade, the current consensus from Bionano Genomics' five analysts is for revenues of US$40m in 2023 which - if met - would reflect a huge 53% increase on its sales over the past ...15 Jan 2021 ... That is the question for those investing in Bionano Genomics (NASDAQ: BNGO). ... The news comes on top of advances in coronavirus and in the ...

About Bionano Genomics Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software.Sep 21, 2023 · SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that its Chinese OEM partner, Ecobono, a distribution company focused on reproductive health products, has obtained reagent Class I registration from China's NMPA for Bionano's DNA isolation products. Ecobono is Bionano’s third Chinese OEM ... SAN DIEGO , Sept. 28, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics , Inc. (Nasdaq: BNGO) today announced the publication of the first peer-reviewed benchmarking study to compare optical genome mapping (OGM) to the current global standard in molecular analysis of constitutional genetic disorders,– Acquisition of BioDiscove ry transforms Bionano from the structural variation company into a data solutions provider with the potential to offer the most comprehensive variant analysis platform in genomics – Total revenue of $4.7 million , a 112% year-over-year total revenue increase, driven byAug 14, 2023 · SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Gülsen Kama will serve as its next Chief Financial Officer (CFO), effective September 11, 2023. Christopher Stewart, who held the position of CFO since September 2020, will stay on during the transition and then move into an advisory role.

BNGO | Complete Bionano Genomics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.The Bionano Genomics news today caught the interest of investors. More than 73 million shares of the stock have traded hands already this morning. For comparison, the company’s average daily ...

Nov 1, 2023 · Company Contact: Erik Holmlin, CEO Bionano Genomics, Inc. +1 (858) 888-7610 [email protected] Investor Relations: David Holmes Gilmartin Group +1 (858) 888-7625 [email protected] Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine.About Bionano Genomics Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software.The market for genomics products and services is significant, expected to grow at a CAGR of 10.2% from 2017-2022, reaching $23.9 billion by 2022. Bionano is targeting two types of end users. First ...SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the publication by scientists at Revvity Omics (formerly Perkin Elmer Genomics), Leiden University Medical Centre, Bombay Hospital, and UT Dallas, of the largest peer-reviewed study to date on the use of optical genome mapping (OGM) to diagnose facioscapulohumeral muscular dystrophy (FSHD).View the latest Bionano Genomics Inc. (BNGO) stock price, news, historical charts, analyst ratings and financial information from WSJ.Track Bionano Genomics Inc (BNGO) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors SAN DIEGO , Jan. 10, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics , Inc. (BNGO) today announced its 2023 Symposium, which is the quintessential event for the optical genome mapping (OGM) community to present its progress to the world. It will feature four consecutive days of OGM presentationsNov 3, 2022 · SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today reported financial results for the third quarter ended September 30, 2022. Following the downgrade, the current consensus from Bionano Genomics' five analysts is for revenues of US$40m in 2023 which - if met - would reflect a huge 53% increase on its sales over the past ...

SAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication in Nature Communications demonstrating the utility of optical genome mapping (OGM) as an alternative to karyotyping (KT) and chromosomal microarray (CMA) for the evaluation of CRISPR-Cas9 edited human induced pluripotent stem cell (iPSC) lines in order to uncover possible pathogenic ...

Sep 30, 2022 · Nov. 08, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended Business Updates Since the End of Q3 2023 Q3 2023 Highlights 6,176 nanochannel array flowcells sold during the third quarter Initiated early access program for Stratys™ system , which are ongoing, $1,863.22

SAN DIEGO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced that its Chinese original equipment manufacturing (OEM) partner, Beijing Genome Precision Technology (BGPT), a comprehensive molecular diagnostics company, has obtained reagent class I registrations from China's National Medical Products Administration ...Positive. Nikkei 225. 33,431.51. -0.17%. Negative. Source: LSEG - data delayed by at least 15 minutes. Get Bionano Genomics Inc (BNGO.OQ) real-time stock quotes, news, price and financial ...May 10, 2023 · For full-year 2023, Bionano reiterated its revenue guidance of $35.0 million to $38.0 million. The company’s Q2 revenues are expected to be in the range of $7.8 million to $8.3 million. In early morning trading on the Nasdaq, Bionano's shares were up about 7 percent at $.79. The current analyst consensus has Bionano Genomics, Inc. losing around 45 cents a share in FY2023 as sales rise nearly 30% to $35.7 million. Revenue growth is projected to accelerate by over 70% ...Third quarter 2023 non-GAAP operating expense was $31.8 million, compared to $26.3 million in the third quarter of 2022 and $34.6 million in the second quarter of 2023. Third quarter 2023 non-GAAP ...Bionano Genomics shares will start to get out of their current rut. It’ll start breaking out of its current $5-$6 per share trading range. After that, it’ll be up to other factors to help fuel ...SAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced two publications detailing results from the clinical trial designed to support establishing optical genome mapping (OGM) as part of the standard of care (SOC) in diagnosis of genetic disease for postnatal patients. The clinical trial is designed to ...CONTACTS. SAN DIEGO , Aug. 04, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-10. The effective time of the reverse stock split will be 5 p.m. ET on August 4, 2023.Bionano Genomics. SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Gülsen Kama will serve as its next Chief Financial Officer (CFO ...Publication demonstrates that Saphyr can be powerful and easy to use for solid tumor analysis in cancer research and clinical testing. SAN DIEGO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), announced the publication of a method for using optical genome mapping (OGM) to identify structural variants (SVs) that drive cancer in a wide variety of solid tumor samples.SAN DIEGO , May 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics , Inc. (BNGO), today announced that on May 1, 2023, it published an open letter to stockholders in support of its proposals at its upcoming annual meeting of stockholders, a copy of which is included at the end of this press release.Dec 1, 2023 · Headline. After Plunging -23.84% in 4 Weeks, Here's Why the Trend Might Reverse for Bionano Genomics, Inc. (BNGO) finance.yahoo.com - November 17 at 2:20 PM. Analysts Offer Insights on Healthcare Companies: BioNano Genomics (BNGO) and Ascendis Pharma (ASND) markets.businessinsider.com - November 16 at 11:51 PM.

We believe this technology-centric view is holding us back from the answers to critical questions around the origin, diagnosis, severity and treatment of cancer and genetic disease. We believe the way to move forward is an inclusive one that reveals what other tools miss and unifies data across technologies into one view to maximize the ... SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced that it has entered into a definitive agreement to acquire BioDiscovery, Inc., a leading software company ...SAN DIEGO, October 12, 2021 (GLOBE NEWSWIRE) - Bionano Genomics, Inc. (BNGO) today announced that it has entered into a definitive agreement to acquire BioDiscovery, Inc., a leading software company with best-in-class solutions for analysis, interpretation and reporting of genomics data.Instagram:https://instagram. annonymous llcbest moving stock todaymolina healthcare ratingscan i paper trade options A-smart is Bionano’s second Chinese OEM partner to obtain approval from NMPA for the Company’s optical genome mapping (OGM) solutions. NMPA issued two approvals to A-smart: one for Bionano’s G2 direct label and stain (DLS) DNA labeling kit and one for Bionano’s G2 SP bone marrow aspirate (BMA) DNA isolation kit. vtsax mutual fundblue chip.art Mar 31, 2022 · UPDATE - Bionano Announces Preliminary Q1 2023 Results and Business Updates. Preliminary Q1 total revenue expected to be between $7.3 and $7.5 million, which would represent an estimated increase of 28% to 32% over Q1 2022. Installed base of Saphyr® systems reached 259 as of March 31, 2023, which represents growth of the installed base by 19 ... is webull day trading Bionano Genomics, Inc. misses on earnings expectations. Reported EPS is $-1 EPS, expectations were $-0.75. Operator: Good day, and welcome to the Bionano's Third Quarter 2023 Earnings Conference Call.News Release Details « Back. Bionano Genomics Reports Preliminary Fourth Quarter and Full-Year 2022 Results. Jan 05, 2023 | PDF Version - Preliminary Q4 revenue expected to be between $8.1 and $8.4 million; 29% to 33% increase over Q4 2021 - Reached installed base of 240 systems as of YE 2022; 46% increase over YE 2021 ...